Avenue Therapeutics Ownership
| ATXI Stock | USD 0.38 0.02 5.56% |
Avenue |
Avenue Pink Sheet Ownership Analysis
About 25.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.33. Some equities with similar Price to Book (P/B) outperform the market in the long run. Avenue Therapeutics recorded earning per share (EPS) of 24.78. The entity had not issued any dividends in recent years. The firm had 1:75 split on the 26th of April 2024. Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acuteintensive care hospital setting. The company was incorporated in 2015 and is based in New York, New York. Avenue Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.The quote for Avenue Therapeutics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Avenue Therapeutics please contact the company at 781 652 4500 or go to https://www.avenuetx.com.Avenue Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avenue Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avenue Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avenue Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avenue Therapeutics Outstanding Bonds
Avenue Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avenue Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avenue bonds can be classified according to their maturity, which is the date when Avenue Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| AVNT 7125 01 AUG 30 Corp BondUS05368VAA44 | View | |
| AVERY DENNISON P Corp BondUS053611AJ82 | View | |
| AVY 225 15 FEB 32 Corp BondUS053611AM12 | View | |
| US053611AK55 Corp BondUS053611AK55 | View | |
| US05369AAA97 Corp BondUS05369AAA97 | View | |
| ACGCAP 195 30 JAN 26 Corp BondUS05369AAK79 | View | |
| US05369AAD37 Corp BondUS05369AAD37 | View | |
| ACGCAP 195 20 SEP 26 Corp BondUS05369AAL52 | View |
Currently Active Assets on Macroaxis
Other Information on Investing in Avenue Pink Sheet
Avenue Therapeutics financial ratios help investors to determine whether Avenue Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avenue with respect to the benefits of owning Avenue Therapeutics security.